Phase I trials have evolvedEU Legislative developments have redefined the boundaries of Phase I and opened a new era of opportunity to expedite compounds through the Early Phases. Pharmacology and patient studies can now be integrated or work independently of one another. Clinical & therapeutic innovations now enable Early Phase research to deliver more dynamic and insightful studies, maximizing the probability of a compound reaching the later Phases. We have put together the definitive one-day seminar to explore the new boundaries of Phase I.Click here for more information

Latest news

Richmond Appoints Lisa Campbell as Director of Regulatory Strategy

April 23, 2025
Richmond Pharmacology is pleased to announce the appointment of Lisa Campbell as Director of Regulatory Strategy
Read more

Von Willebrand Disease Trial – First Stage of Hemab Therapeutics’ Trial Completed and New Patients Invited to Enrol

April 2, 2025
Richmond has completed dosing the first cohort of patients in Velora Pioneer, a phase 1/2 clinical trial investigating Hemab...
Read more

Events

Swiss Biotech Day 2025

5–6 May 2025
Richmond Pharmacology is pleased to confirm our participation at Swiss Biotech Day 2025
View event